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 Abstract. Conjugated linoleic acid (CLA) has been reported to 
exert beneficial physiological effects on body composition and the 
immune system. However, little information is available on the 
influence of CLA on immune function during early life periods. 
The present study evaluates the effect of feeding an 80:20 mixture 
of cis-9,trans-11- and trans-10,cis-12-CLA isomers during 
gestation, suckling and early infancy on the systemic and mucosal 
immune responses of Wistar rats at three different time points: at 
the end of the suckling period (21-day-old rats), in early infancy 
(28-day-old rats), and later in life (adulthood). Cis-9,trans-11- and 
trans-10,cis-12-CLA isomers were detected in the milk of CLA-fed 
dams and in the plasma of all CLA-supplemented pups, and the 
highest content was achieved in those rats supplemented over the 
longest period. Dietary supplementation with that CLA mix 
enhances the systemic  production  of  the main in vivo and ex vivo 
immunoglobulin (Ig) isotypes in 21- and 28-day-old rats. 
Moreover, CLA supplementation during suckling and early infancy 
also enhances the humoral immune defenses at intestinal level, by 
means of mucosal IgA increase, whereas down-regulates the 
systemic   lymphoproliferative   response.   Finally,          we   described  
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herein how feeding a diet enriched with the same isomer mix of cis9,trans11- and 
trans10,cis12-CLA from gestation to adulthood improves the capacity of adult rats to 
achieve a specific systemic and mucosal immune responses. All these data support the 
immunomodulatory effects of dietary supplementation of CLA, particularly of the 
cis9,trans11-CLA isomer, during early stages of life on immune system development, 
as well as the long-term effects on the specific immune response in adult age. 
  
Introduction 
 
 Birth is for the newborn a transition from a sterile environment to a 
world full of bacteria and viruses, where protection is crucial. During the first 
stages of life, antibodies from the mother are transferred to the foetus and the 
child decrease the number of infectious episodes caused by microorganisms 
to which exist maternal immunological memory [1,2]. The immune system is 
in constant evolution, and their function is profoundly influenced by 
maternal, environmental, dietary, and behavioural factors. Although the 
impact of these factors is greatest during the prenatal and immediate postnatal 
periods, their influence extends beyond this period. Patterns of development 
in postnatal life determine many of the immune outcomes in later life [3].  
 Over the last years, the effect of nutrition on the development of the 
immune system has acquired great interest and has led to adoption of the term 
“immunonutrition”. Because breast milk is the only natural food for 
newborns, and dietary contact has a pivotal role in the development of their 
immune system, significant progress has been made in the characterisation of 
milk components affecting growth, development and functions of the 
gastrointestinal tract and the immune system [4]. In this sense, breast milk is 
rich in, among others, immunoglobulins (Ig) that can bind and neutralise 
pathogens in the intestinal tract; bactericidal factors such as lactoferrin, 
lactoperoxidase and lysozyme and growth factors, nucleotides and cytokines 
that improve immune defence and gut-barrier function [5]. Besides these 
compounds, the dietary lipids present in breast milk have been studied with 
special attention. In this sense, it has been suggested that polyunsaturated 
fatty acids (PUFA), specifically docosahexaenoic acid and arachidonic acid, 
which constitute a relatively low fraction of the total fatty acids in human 
breast milk, participate in neonate immune development [6]. 
 Human milk contains measurable quantities of conjugated linoleic acid 
(CLA), a class of positional and geometric conjugated dienoic isomers of 
linoleic acid. The predominant CLA isomer in milk and dairy products is    
cis-9,trans-11 (c9,t11)-CLA, also called rumenic acid, which ranges in 
human milk from 83 to 100% of total CLA [7,8]. The trans-10,cis-12 
(t10,c12)-CLA isomer is also found in dairy products, although in lower 
proportion than rumenic acid [8,9], but even very low doses of the t10,c12-
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CLA isomer seem to have large biological effects [10]. The concentration of 
CLA in milk is influenced by the intake of food of ruminant origin [8].  
 CLA has been reported to exert beneficial physiological effects on body 
composition and inhibition of carcinogenesis, atherosclerosis, and diabetes 
[11-14]. Moreover, CLA isomer mixtures have been shown to modulate 
immune function in vitro and in vivo [15-19]. Results from these studies 
show great variability, partly because of differences in the experimental 
animal species used and the length of the studies, but also because of 
differences in the isomer mixtures used for supplementation. However, little 
work has been done on the immunomodulatory effects of CLA during the 
early postnatal periods (lactation or infancy), and even less during the 
prenatal period (gestation).  
 The present study evaluates the influence of dietary supplementation 
during gestation, suckling, and early infancy with an 80:20 isomer mix of 
c9,t11- and t10,c12-CLA on the systemic and mucosal immunity in Wistar 
rats at the end of the suckling period (21-day-old rats), in early infancy     
(28-day-old rats), and later in life (adulthood). 
  
1. Dietary supplementation with CLA during early life on the 
development of the immune system in rats   
 
 The aim of this part of the study was to evaluate the effect of dietary 
supplementation during early life with an 80:20 isomer mixture of c9,t11- 
and t10,c12-CLA on the development of the immune system in Wistar rats. 
CLA supplementation was performed during three life periods: gestation, 
suckling, and early infancy. For that purpose, the immunomodulatory effects 
of dietary CLA during gestation and suckling were evaluated in 21-day-old 
rats (at the end of the suckling period) [20]. And, on the other hand, the 
influence of CLA supplementation limited to suckling period and to early 
infancy was evaluated in 28-day-old rats (early infant rats, 1 wk after 
weaning) [21]. Moreover, as it has been suggested that CLA intake during 
early stages of development may have effects later in life [22,23], we have 
also studied whether CLA supplementation limited to suckling produces 
effects which can last until early infancy  [21]. 
 At both ages, their immune system is still in maturation (i.e., antibody 
production), however, in 28-day-old rats some immune functions are similar 
to those of adult animals (i.e., lymphoproliferative response). To investigate 
the immunomodulatory ability of CLA supplementation on the immune 
system of 21- and 28-day-old rats, both systemic and mucosal immune 
responses were evaluated [20,21,24]. 
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1.1. Experimental design           
 
 Animals were distributed in eight experimental groups according to the 
total period of CLA supplementation, administration route used, and age at 
the time immune status was assessed (21- or 28-day-old) (Fig. 1).   
 
 Day 21 assessment: Pregnant Wistar rats at 7 days’ gestation were 
randomly assigned to one of the following four dietary groups, and pups from 
these groups were sacrificed at the end of the suckling period (21- day-old):  
 
- 21/5* group: Pups from dams fed a 1% CLA diet during the last 2 
weeks of gestation and throughout the suckling period. During 
suckling, the pups received CLA through the dams’ milk. The total 
period of supplementation was 5 wk.  
- 21/5 group: Pups from dams fed a 1% CLA diet during gestation and 
a standard diet during suckling. During suckling, pups were CLA-
supplemented daily by oral (p.o.) administration. The total period of 
supplementation was 5 wk.  
- 21/3 group: Pups from dams fed the standard diet during gestation and 
suckling. Pups received CLA daily by p.o. administration throughout 
the suckling period. The total period of supplementation was 3 wk.  
- 21/0 group (Ref): Pups from dams fed the standard diet throughout 
the study. These animals constitute the reference diet group. The 
total period of supplementation was 0 wk.  
 
 Day 28 assessment: On the day of birth, pups from dams fed standard diet 
during gestation were randomly assigned to one of the following four dietary 
groups. All dams were fed standard diet throughout the period of study. Pups 
from these groups were sacrificed 1 week after weaning (28- day-old).  
 
- 28/4 group. Pups received CLA daily by p.o. administration during 
 suckling; after weaning, animals were fed 1% CLA diet from day 21 
 to 28 (early infancy). The total period of supplementation was 4 wk. 
- 28/3 group. Pups received CLA daily by p.o. administration during 
 suckling; after weaning, animals were fed standard diet up to day 28. 
 The total period of supplementation was 3 wk. 
- 28/1 group.  Pups received 1%  CLA diet  exclusively for one week 
 after weaning (days 21–28). The total period of supplementation was 
 1 wk. 
 - 28/0 group (Ref). Pups fed standard diet during suckling and early 
  infancy. These animals constitute the reference diet group. The total 
  period of supplementation was 0 wk.  
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Figure 1. Diagram of the experimental design beginning on day 7 of gestation until 
day 21 of suckling or day 28 of life. 1 CLA arrives at the foetus by transplacental 
transfer. 2 CLA arrives at  pups through the dams’ milk. 3 Total period of CLA 
supplementation from gestation until the end of suckling. 4 Total period of CLA 
supplementation from the day of birth until 1 wk after weaning.   
 
1.2. Dietary CLA supplementation      
 
 The standard diet used in this study corresponded to the American 
Institute of Nutrition (AIN)-93G formulation, containing 7% soybean oil. The 
1% CLA diet was obtained from modified standard flour AIN-513 (Harlan) 
containing 10 g CLA/kg [20]. Thus, the supplemented diet contained 6% 
soybean oil plus 1% CLA oil. The CLA isomer mixture was approximately 
80% c9,t11 and 20% t10,c12 from the total CLA isomers in oil. This 
proportion has been chosen due to its resemblance to that one present in 
breast milk [7]. CLA oil was kindly supplied by Loders Croklaan (Lipid 
Nutrition, Wormerveer, The Netherlands). The 1% CLA diet in suckling 
animals corresponded to a daily administration of 1.5 mg CLA oil provided/g 
of rat body weight from day 1 to 21. 
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1.3. Relative CLA concentration in dams’ milk   
 
 In order to confirm the CLA transfer from dams to pups through milk, we 
collected milk from dams on day 21 post-partum [20] and evaluated the 
content of c9,t11- and t10,c12-CLA isomers by fast gas chromatography, as 
previously described [25] (Table 1). The results showed that, at the end of 
suckling (day 21), milk from dams fed the CLA diet during gestation and 
suckling showed higher concentrations of the c9,t11- and t10,c12-CLA 
isomers than rats fed the standard diet. Moreover, the presence of a small 
quantity of c9,t11- and not of t10,c12-CLA in the milk of non-supplemented 
rats supports the concept that rats produce rumenic acid (c9,t11-CLA), as has 
been suggested by other authors, by conversion of free linoleic acid by the 
intestinal bacterial flora [26] or by the endogenous conversion of trans-
vaccenic acid, present in vegetable oils contained in standard diets [27]. 
 On the other hand, the proportion of these two isomers in milk, 86:14, 
varied from that supplemented to dams, 80:20 (Table 1). The lower 
proportion of t10,c12-CLA than that initially supplemented is probably due to 
the faster metabolism of this isomer. It has been reported that t10,c12-CLA 
activates the β-oxidation system more strongly than c9,t11-CLA in rats; 
therefore, the former could easily become oxidised [28]. 
 
Table 1. Relative content of c9,t11- and t10,c12-CLA isomers in dams’ milk and in 
the plasma of  21- and 28-day-old pups (% total fatty acids).  
 
 c9,t11-CLA1 t10,c12-CLA1 
Dams milk: standard diet 0.02 ± 0.00 0.00 ± 0.00 
Dams milk: CLA diet 2.93 ± 0.11** 0.46 ± 0.02** 
Plasma: 21/5* group 1.34 ± 0.01*σϖ 0.21 ± 0.01*σϖ 
Plasma: 21/5   group 1.78 ± 0.05*σ 0.13 ± 0.01*σ 
Plasma: 21/3   group 0.90 ± 0.01* 0.05 ± 0.00* 
Plasma: 21/0   group 0.15 ± 0.01 N.D. 
Plasma: 28/4  group 1.31 ± 0.03*φΨ 0.13 ± 0.01*φΨ 
Plasma: 28/3   group 0.44 ± 0.03*φ 0.05 ± 0.00*φ 
Plasma: 28/1   group 1.23 ± 0.03* 0.08 ± 0.00* 
Plasma: 28/0   group 0.15 ± 0.01 N.D. 
 
 
1 Values are expressed as mean ± SEM (n= 4-7 dams/group; n= 10 
pups/group). N.D., non-detectable. Significant differences: **P<0.001 vs. 
standard diet group; *P<0.05 vs. age-matched reference group (21/0 or 28/0); 
σP<0.05 vs. 21/3; ϖP<0.05 vs. 21/5; φP<0.05 vs. 28/1; ΨP<0.05 vs. 28/3. 
Modified of Ramírez-Santana et al. [20,21].  
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1.4. Relative CLA concentration in rat plasma     
 
 Once confirmed that the CLA from the dams’ diet was able to be 
transferred through dams’ milk to pups, the efficiency in the incorporation of 
such PUFA from milk or directly by p.o. was also evaluated in the pups 
[20,21]. Therefore, the content of c9,t11- and t10,c12-CLA isomers in the 
plasma of 21- and 28-day-old pups was quantified by fast gas 
chromatography (Table 1). Regarding the concentration of CLA in the 
plasma of pups determined on the day of weaning, pups from group 21/0 
(Ref) showed a low plasma content of c9,t11-CLA and no t10,c12-CLA. 
Groups 21/5*, 21/5 and 21/3 had approximately nine, twelve and six times 
higher levels of c9,t11-CLA than group 21/0, respectively. Moreover, the 
plasma CLA content in the groups supplemented with the 80:20 CLA mix 
during gestation and suckling (21/5* and 21/5 groups; 5 wk) was ∼ 1.5 and 2 
times higher, respectively, than that of animals supplemented only during 
suckling (21/3 group; 3 wk) (Table 1).  
 These results demonstrate that CLA was absorbed by all the supplemented 
animals since c9,t11- and t10,c12-CLA isomers were detected in the plasma of 
all 21-day-old rats fed CLA. They also indicate that CLA, besides being 
incorporated after CLA p.o. supplementation, was also able to be transferred 
from dams to pups during suckling. However, these results cannot demonstrate 
that CLA transfers through the placenta, since the plasma of newborns was not 
analysed. Nevertheless, Chin et al. [29] found a 20-fold increase of CLA in the 
liver of foetuses (at day 20 of gestation) from dams fed a 0.5% CLA diet during 
gestation than in foetal livers coming from dams fed a control diet. This, 
together with our findings of a higher content of c9,t11- and t10,c12-CLA in 
the milk of rats fed CLA than in those fed the standard diet and the higher 
content of this isomer in 21/5 group plasma than in 21/3 group, confirms that 
CLA is transferred through the placenta to the foetus, as well as through the 
milk to the pup. The highest plasma CLA values in pups from 21/5 group may 
be due to CLA transfer during suckling from the maternal stores accumulated 
during gestation, besides supplementation by p.o. administration.  
 Similarly to that occurred in dams’ milk after CLA intake, the 
supplemented proportion of c9,t11- and t10,c12-CLA (80:20) changed in all 
the groups (Table 1). The proportion of CLA isomers was 86:14, 93:7 and 
94:6 for groups 21/5*, 21/5 and 21/3, respectively. Hence, group 21/5 
presented a higher content of c9,t11-CLA, but a lower content of t10,c12-
CLA than group 21/5*. Moreover, differences between 21/5* and 21/5 
groups in the proportion of CLA isomers in pups’ plasma may be due to the 
influence of the food matrix in 21/5* group, as milk is one of the major 
factors that affect PUFA bioavailability [30]. 
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 Regarding the concentration of CLA isomers quantified in plasma from 
28-day-old animals (Table 1), plasma from reference rats (28/0 group) had 
no t10,c12-CLA and a low content of c9,t11-CLA, which were lower than 
those found in the rest of the groups. The animals who received CLA 
supplementation continuously during suckling and early infancy (28/4 group; 
4 wk) showed the highest content of both CLA isomers among the groups. 
However, rats from the 28/3 group (3 wk) presented lower content of both 
CLA isomers in plasma than rats from the 28/1 group (1 wk). And, again, as 
showed for dams’ milk and 21-day-old pups’ plasma, the relative proportion 
between c9,t11- and t10,c12-CLA was higher in all CLA-supplemented 
groups (28/4, 91:9; 28/3, 90:10; 28/1, 94:6) than that of the original mixture 
(80:20).  
 These results match with the above data concerning 21-day-old animals 
and with other PUFA studies using similar experimental designs [31]. The 
highest content of CLA in plasma was achieved in the longest and continuous 
CLA supplementation (28/4 group), whereas the group that received CLA for 
3 wk and then nothing for 1 wk (28/3 group) exhibited lower CLA plasma 
content than the 28/1 group which only received CLA for the last week. 
Previous interventional studies have shown that the proportion of fatty acids 
in the dietary supplement is highly correlated to that one found in plasma and 
membrane [32]. Therefore, we can suggest that in our study, just finishing the 
supplementation period, CLA plasma levels are an indicative measure of the 
CLA incorporated in the cell membranes, in our case for 28/4 and 28/1 
groups. But this is not the case for the 28/3 group due to the time lapse 
between the last CLA intake and the day of quantification of CLA plasma 
content. The CLA membrane incorporation suggested here agrees with the 
study of Subbaiah et al. [33], which demonstrates that CLA is incorporated 
into cell membranes to varying extent, depending upon the experimental 
conditions.  
 On the other hand, the relative proportion of c9,t11/t10,c12 in the plasma 
of CLA-supplemented animals (∼90:10) is higher than in the original isomer 
mixture (80:20) administered to the animals. These changes in proportions 
could be attributed to the isomer-differentially β-oxidation induction above 
commented (see section 1.3). However, although it has been described that 
both isomers have similar absorption rates in adult rat intestine [34], it is 
possible that young rodents preferentially absorb the c9,t11-CLA isomer. 
Additionally, although no t10,c12-CLA was found in the plasma of reference 
animals (28/0), small quantities of c9,t11-CLA isomer were detected, which 
would indicate an endogenous production of c9,t11-CLA, as previously 
described [26], and, therefore, its influence on the c9,t11/t10,c12 ratio 
observed in plasma. 
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1.5. Immunoglobulin concentration in dams’ milk  
 
 One of our objectives was to evaluate the modulation on the Ig response 
in pups due to CLA, either coming through the milk or directly by p.o. 
administration. However, it has been described that IgA and IgG have a local 
mammary gland production [35], and are absorbed by pups from the ingested 
milk through the intestinal mucosa and extended beyond this compartment. 
Therefore, to better dissect the direct effect of CLA on Ig production by pups, 
we first evaluated the CLA influence on IgA, IgG and IgM concentrations in 
dam’s milk whey at the end of the suckling period [20].  
 As can be shown in Figure 2, the predominant Ig present in rat milk was 
IgG (~280 μg/mL), followed by IgA (~30 μg/mL) and finally IgM (~5 
μg/mL). Dams had a milk concentration pattern of IgG > IgA > IgM, which 
agrees with that described by Dahlgren et al. [35]. This pattern was 
maintained in dams fed the CLA diet, although IgG and IgA concentrations, 
the main Ig isotypes in rat milk, were much higher in these rats. Specifically, 
dams fed the CLA diet during gestation and suckling increased the 
concentration of IgG and IgA, about 6- and 2-fold, respectively. Thus, rat 
milk from CLA fed dams not only transfers CLA to pups, but also high 
concentrations of antibodies.  
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Figure 2. CLA effects on IgA (A), IgG (B) and IgM (C) of rat milk collected on day 
21 of the suckling period. IgA, IgG and IgM concentrations were quantified by 
ELISA in milk whey supernatant fractions after centrifugation and fat layer 
discarding. Values are expressed as mean ± SEM (n= 4-7). Significant differences: 
*P<0.05 vs. standard diet. Modified of Ramírez-Santana et al. [20]. 
 
1.6. Effect of CLA on the development of the systemic immunity in rats 
 
 As had been mentioned before, this study evaluated the effect of CLA on 
the systemic immune response in Wistar rats. For that purpose, we quantified 
serum Ig concentrations, spleen cell proliferation and cytokine secretion 
ability and ex vivo splenocyte Ig production as biomarkers of systemic 
immune development [20,21]. 
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1.6.1. Serum immunoglobulin concentration     
 
 This study evaluated the effect of feeding an 80:20 CLA isomer 
mixture during gestation and/or suckling and/or early infancy in the 
incipient antibody production of suckling and early infant rats. For that, 
serum IgG, IgM and IgA concentrations were quantified in 21- and 28-
day-old animals from all the groups included in the exhaustive 
experimental design (Fig. 3).  
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Figure 3. CLA effects on serum IgG, IgM and IgA from 21- and 28-day-old animals. 
Serum IgG (A, B), IgM (C, D) and IgA (E, F) concentrations were quantified by 
ELISA at the end of the suckling period (day 21; A, C, E) and 1 week after weaning 
(day 28; B, D, F). Values are expressed as mean ± SEM (n= 15-20). Significant 
differences: *P<0.05 vs. age-matched reference group (21/0 or 28/0); σP<0.05 vs. 
21/3; ϖP<0.05 vs. 21/5; φP<0.05 vs. 28/1; ΨP<0.05 vs. 28/3. Modified of Ramírez-
Santana et al. [20,21].  
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 Regarding the results obtained from the 21-day-old animals, those from 
the group 21/0 (Ref) showed ∼5 mg/mL of IgG (Fig. 3A), ∼95 μg/mL of IgM 
(Fig. 3C) and ∼2.7 μg/mL of IgA (Fig. 3E). CLA supplementation for 5 wk, 
2 wk during gestation and 3 wk during suckling through the dams’ milk 
(21/5* group), increased the total Ig serum concentration almost 4-fold, 
mainly by enhancement of IgG. At this age, there were no differences in 
serum IgM concentration among the groups. However, 21/5* group exhibited 
a lower IgA serum concentration than those of the other groups.  
 With respect to 28-day-old animals, rats from the 28/0 group (Ref) had 
∼2 mg/mL of IgG (Fig. 3B), ∼80 μg/mL of IgM (Fig. 3D) and ∼8 μg/mL of 
IgA (Fig. 3F). Similarly to that observed in younger animals, those that 
received CLA diet during and after suckling (28/4 group) showed higher 
serum IgG, IgM and IgA concentrations than those receiving CLA only for   
1 week after suckling (28/1) and rats from the 28/0 group. Moreover, rats 
from the 28/3 group, i.e., those receiving CLA diet only during suckling, 
showed 3 times the IgG concentration than those from the 28/1 and 28/0 
groups. Considering total serum Ig, CLA supplementation during suckling 
(28/4 and 28/3 groups) increased the Ig concentration 4-fold compared to the 
28/1 and 28/0 groups, mainly by increasing IgG.  
  All  these  results show the enhancing properties of CLA on the main      
in vivo serum Ig isotype, IgG. However, this effect was not observed in all 
the supplemented groups, a fact that underlines the importance of continuous 
CLA supplementation during gestation and suckling (21 day assessment), or 
during suckling and early infancy (28 day assessment). This immuno-
enhancing effect has already been reported in older animals, as by Sugano et 
al. [15] in 7-week-old rats receiving 1% CLA (50:50 isomer mix), showing 
an increase in serum IgA, IgG and IgM concentrations and a decrease in IgE. 
Song et al. [36] reported a similar effect in human subjects following 
supplementation with a 50:50 isomer mixture for 12 wk. Nevertheless, 
Yamasaki et al. [37] found no significant effect on serum IgA, IgG or IgM 
concentrations after feeding 5-week-old rats for 3 wk with a 50:50 CLA 
isomer mixture at doses ranging from 0.05 to 0.5%. Discrepancies with the 
study reported by Yamasaki et al. [37] might be due to the low doses of CLA 
tested in that study. Studies carried out in other species during gestation and 
lactation periods have also reported serum IgG increases [38,39], in keeping 
with the present results.  
 With respect to the serum IgA decrease observed in the present study 
after CLA supplementation during gestation and suckling, Turpeinen et al. 
[40]
 
also detected an IgA reduction in subjects with birch pollen allergy 
supplemented for 12 wk with a CLA mixture containing 63,5% of c9,t11. 
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Yamasaki et al. [37] found a slightly lower concentration of serum IgA after 
feeding the 0.5% CLA dose, although the reduction was not significant. 
Considering that IgA is the main Ig in the gut surface (80–90%) and the fact 
that systemic IgA-plasma cells continuously migrate to the intestinal wall 
[41], the serum IgA decrease should not be interpreted as harmful. In fact, 
this serum IgA decrease is accompanied by an increase in intestinal IgA in 
CLA-supplemented weaned rats [24; see section 1.7.1.]. We also have 
reported an increase in mucosal IgA after a specific challenge in adult rats 
following this CLA diet through life [42; see section 2.3.].   
 
1.6.2. Ex vivo spleen immunoglobulin production        
 
 The CLA immunoenhancing effects on antibody synthesis, observed 
upon the supplementation of c9,t11-  and t10,c12-CLA isomers at 80:20 ratio 
in vivo in suckling and infant rats, were also studied ex vivo. With this 
purpose, IgM and IgG production by unstimulated spleen cells, from animals 
corresponding of all groups, were quantified after 7 days of culture [20,21].  
 The spontaneous IgM and IgG production by splenocytes from 21-day-
old rats showed that IgM was the main isotype found in supernatant fractions 
(Fig. 4A), being forty times higher than IgG (Fig. 4B). Regarding CLA 
supplementation, IgM production from both groups supplemented for 5 wk 
(21/5* and 21/5 groups, ∼900–1200 ng/mL) was higher than that of the 
groups supplemented for 3 wk (21/3 group) and 0 wk (21/0 group) (both 
∼500 ng/mL). However, this increase was only significant when pups 
received CLA during gestation and suckling by p.o. administration (21/5 
group) (Fig. 4A). Otherwise, IgG production was very low (∼10 ng/mL) and 
no differences were found among groups (Fig. 4B). Thus, continuous CLA 
supplementation during gestation and suckling enhances splenocyte IgM 
production, increasing total Ig concentration by almost 2-fold that of non-
supplemented animals.  
 With respect to 28-day-old assessment, IgM was also the predominant 
isotype found in supernatants (Fig. 4C), being ∼100 times higher than IgG 
production (Fig. 4D). The groups supplemented with CLA during suckling 
(28/4 and 28/3 groups) synthesised higher IgM and IgG levels than the 
reference group (28/0), but it was only significant in the 28/3 group. This fact 
indicates the lasting of the CLA effect on the Ig synthesis later in life, or at 
least 1 week after finishing the CLA intake. Spleen Ig production from the 
28/1 and 28/0 groups was similar.  
 Overall, in the present study, CLA supplementation in early life 
enhanced spleen IgM production. These results agree with other studies 
carried   out  in  older  rats,   which  reported       enhancement  of  splenocyte  Ig 
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Figure 4. CLA effects on spleen cell Ig production from 21- and 28-day-old animals. 
IgM (A, C) and IgG (B, D) concentrations in supernatants after 7 days of spleen cell 
culture were quantified by ELISA at the end of the suckling period (day 21; A, C) and 
1 week after weaning (day 28; B, D). Values are expressed as mean ± SEM (n= 15-
20). Significant differences: *P<0.05 vs. age-matched reference group (21/0 or 28/0); 
σP<0.05 vs. 21/3. Modified of Ramírez-Santana et al. [20,21].  
 
production after feeding 50:50 CLA isomer mixtures [15,37]. In addition, 
some authors have reported this increase in old mice after feeding the pure 
t10,c12-CLA isomer [43]. Although the present results confirmed the 
immunoenhancing effect of the c9,t11 isomer, we cannot rule out immune 
functions for t10,c12-CLA.  
 
1.6.3. Spleen lymphocyte functionality: Proliferation and cytokine secretion   
                                                                        
 Besides the capacity of in vivo Ig production, the influence of dietary CLA 
supplementation on the functionality of ex vivo isolated spleen lymphocytes was 
also evaluated by their ability to proliferate and to produce cytokines.  
 At the end of suckling (21-day-old assessment), the CLA diet did not 
modify the lymphoproliferative capacity in any group (21/5*, 21/5, 21/3), 
measured 72 h after mitogen-stimulation when compared to reference 
animals (21/0) (Fig. 5A). However, in the assessment of older animals (1 wk 
after weaning), CLA supplementation during suckling (28/4 and 28/3 groups) 
Francisco J. Pérez Cano et al. 216 
reduced ex vivo spleen lymphoproliferative ability compared to that in the 28/1 
and 28/0 groups, but it was only significant for the 28/4 group (Fig. 5B). Cell 
viability was slightly reduced after mitogen-stimulation, but, this decrease did 
not differ among groups in 21-day-old evaluation, indicating that CLA dietary 
supplementation had no effect on splenocyte viability. On the other hand, CLA 
supplementation effect on 28-day-old animals conferred more resistance to the 
mitogen toxic effects, as is demonstrated by the lowest mortality of 28/4 group 
among the groups. Thus, the decrease in the proliferation rate cannot be 
attributed to a lower viability caused by CLA diet.  
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Figure 5. CLA effects on proliferation rate in mitogen-stimulated spleen cells from 
21- and 28-day-old animals. Lymphoproliferative response was determined after 
stimulating with phorbol myristate acetate (PMA) plus ionomycin (Io) for 72 h at the 
end of the suckling period (day 21; A) and 1 week after weaning (day 28; B). The 
proliferation rate (%) are expressed relative to the age-matched reference group (21/0 
or 28/0), which was set at 100%. Values are expressed as mean ± SEM (n= 15-20). 
Significant differences: *P<0.05 vs. age-matched reference group (21/0 or 28/0); 
φP<0.05 vs. 28/1. Modified of Ramírez-Santana et al. [20,21].  
 
 Moreover, interleukin (IL)-2 production, the main proliferative signal for 
lymphocytes, was measured in supernatant fractions obtained after 24 h of 
spleen cell stimulation and was not modified by CLA supplementation either 
in 21- or 28-day-old assessment (Table 2).  
 The lack of CLA dietary effect on lymphocyte proliferation found in 21-
day-old rats is in agreement with the results reported by Kelley et al. [16] in 
8-week-old mice after feeding pure isomers of CLA for 56 days, and in 
human subjects either by ingestion of pure isomers [44]
 
or 50:50 and 80:20 
isomer mixtures [16,45]. Since IL-2 plays a central role in the cell-mediated 
immune response by regulating proliferative abilities, it could be expected 
that if CLA does not modify splenocyte proliferation, it will not affect IL-2 
production. The present results are consistent with most other studies in 
animals and human subjects, which have found no significant effects on IL-2 
splenocyte secretion among the dietary groups [43,44,46].  
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Table 2. Content of cytokines in 24 h splenocyte supernatants after mitogen (PMA/Io) 
stimulation1. 
 
Cytokines (day 21) 21/5* group      21/5 group 21/3 group 21/0 group 
 
IL-2 (ng/mL) 4.1 ± 1.1 4.1 ± 1.0 5.6 ± 0.9 4.1 ± 0.8 
IFNγ (ng/mL) 4.6 ± 0.8 5.9 ± 1.0 6.4 ± 1.4 3.7 ± 0.8 
IL-4 (pg/mL) 29.3 ± 7.9 32.4 ± 6.0 (*) 15.9 ± 1.3 12.4 ± 1.8 
IL-10 (pg/mL) 181.7 ± 47.2 176.3 ± 43.8 90.6 ± 8.5 108.0 ± 19.6 
Cytokines (day 28) 28/4 group 28/3 group 28/1 group 28/0 group 
 
IL-2 (ng/mL) 6.2 ± 0.8 6.1 ± 0.8 7.2 ± 1.1 6.8 ± 1.2 
IFNγ (ng/mL) 10.9 ± 1.4 7.1 ± 0.9 7.3 ± 0.8 6.0 ± 1.3 
IL-4 (pg/mL) 27.8 ± 4.0 18.8 ± 2.8 28.7 ± 7.4 17.3 ± 2.4 
IL-10 (pg/mL) 244.4 ± 41.0 224.9 ± 29.2 222.4 ± 34.5 191.6 ± 24.2 
IL-6 (pg/mL) 219.0 ± 38.0*φΨ 40.1 ± 12.9 45.7 ± 15.1 N.D.  
 
1  Values are expressed as mean ± SEM (n= 10). N.D., non-detectable. Significant 
differences: (*) P=0.06 vs. reference group (21/0); *P<0.05 vs. reference group (28/0); 
φP<0.05 vs. 28/1; ΨP<0.05 vs. 28/3. Modified of Ramírez-Santana et al. [20,21].  
 
 Despite the above results, a wide range of PUFA, including CLA, have 
been found to reduce the mitogen-stimulated proliferation of lymphocytes 
isolated from several species [47,48]. Thus, the lack of effect observed in   
21-day-old animals, may be probably due to the immaturity of this function 
(which is acquired later in life) at a very early age [49]. In contrast, the 
mitogen-induced splenocyte proliferation on 28-day-old animals was down-
modulated in the longer-lasting CLA supplementation, similarly to that 
described in adults [42,50,51]. Thus, the age of 28 days is optimal to evaluate 
CLA effects, since at this age CLA still increases antibody production and is 
also able to down-modulate lymphoproliferation. Calder and Newsholme [52] 
reported that some PUFA inhibited lymphocyte proliferation without 
decreasing IL-2 concentration, a fact that is consistent with the present results 
showing that CLA supplementation did not modify IL-2 production. In this 
sense, many studies have described conformation changes in IL-2 receptors 
by PUFA, specifically modifying lipid rafts [53,54]. Thus, CLA, even with 
trans double bonds, could potentially alter membrane structure, including 
lipid rafts, by preventing IL-2Rα migration to soluble membranes, where   
IL-2 signalling occurs and T-cell activation and proliferation are 
consequently induced [53,55,56]. In addition, the anti-proliferative 
lymphocyte effect exhibited by dietary CLA in the present study could be 
mediated by the nuclear peroxisome proliferator-activated receptor (PPAR)γ, 
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because intestinal PPARγ gene expression has been found up-regulated after 
CLA supplementation (see section 1.7.2.) [24]. The PPARγ-dependent CLA 
effect was first described by Bassaganya-Riera and Hontecillas [57] in a pig--
inflammatory bowel disease model, where dietary CLA resulted in intestinal 
disease amelioration and PPARγ gene expression up-regulation.  
 Besides IL-2 quantification, in the present study other cytokines were 
also analyzed in splenocyte supernatants after mitogen-stimulation (Table 2). 
Interferon (IFN)-γ, a T helper 1 (Th1) cytokine, was also secreted in similar 
amounts in all experimental groups. T helper 2 (Th2) cytokines, IL-4 and   
IL-10, were also quantified in the same splenocyte supernatant fractions and 
although no statistical differences were found among groups, due to the large 
intra-group variability, rats from 21/5* and 21/5 groups showed almost 2-fold 
higher values than those observed in 21/3 and 21/0 groups (Table 2). This 
IL-10 increase is in line with studies showing higher IL-10 production by 
dendritic cells incubated with c9,t11-CLA after stimulating with 
lipopolysaccharide [58]. This effect may be related to the anti-inflammatory 
properties attributed to CLA [22,59].  Moreover, by increasing IL-4, CLA 
might be promoting T helper 2 (Th2) responses, such as modulating antibody 
production and inhibiting several cellular functions, which is in agreement 
with the present results regarding CLA enhancement of the principal in vivo 
and in vitro Ig.  
 However, in 28-day-old animals, the concentration of IL-6, which was 
also included in the study, was increased in the 28/4 group compared to the 
28/3 and 28/1 groups, while IL-6 was not detected in the 28/0 group (Table 
2). This result is of interest because IL-6 is clearly defined as a prominent 
regulator of T-cell proliferation and differentiation of Ig-secreting B cells 
[60]. Therefore, it might be suggested that the effects on proliferation -in 
early infant rats- and antibody production -in both suckling and early infant 
rats- induced by CLA could be due to an up-regulation of IL-6 production. 
Further studies should confirm this hypothesis and ascertain the mechanism 
involved.  
 
1.7. Effect of CLA on the development of the mucosal immunity in rats  
   
 As it had been mentioned before, this study also evaluated the effect of 
CLA-supplementation during gestation, suckling, and/or early infancy on 
mucosal immunity (small intestine and colon) in Wistar rats. In these periods, 
their mucosal immune response is still in development. In fact, the mucosal 
immune system of the rat continues developing during the suckling period 
and early infancy, and, as occurs in humans, mucosal Ig production is poor. 
Previous studies have shown that IgM production by lamina propia cells 
CLA immunomodulation in early life  219 
begins during the second week of life in parallel to the phenotypic 
development of B cells in rat intestine, and later, weaker production of IgA 
initiates [61]. For that reason, in this study we quantified intestinal IgA at 
both the gene and protein levels as a biomarker of mucosal immune 
development, and TGFβ and PPARγ gene expression as possible mediators of 
CLA’s immunomodulatory effects [24]. Finally, a broad array of genes was 
studied in that compartment to elucidate other mediators in CLA action.  
 
1.7.1. Effect of CLA on IgA gene expression and IgA protein secretion in 
intestinal mucosa   
  
 IgA gene expression in small intestine and colon was assessed in 21- and 
28-day-old animals from all experimental groups. Dietary CLA did not 
modify IgA gene expression in small intestine or colon at the end of the 
suckling period. However, IgA gene expression in animals continuously 
CLA-supplemented during suckling and early infancy (28/4 group; 4 wk) was 
up-regulated almost 5-fold (Fig. 6A, 6B). This increase was seen in both 
tissues analyzed as compared with the reference group (28/0). 
Supplementation limited to the suckling or early infancy periods failed to 
produce this immunoenhancing effect (Fig. 6A, 6B). 
 In addition to detection of changes in gene expression, IgA protein 
concentration was quantified in intestinal washes of 28-day-old animals (Fig. 
7). IgA content was statistically higher in animals CLA-supplemented for 4 
weeks (28/4 group) than in animals in the 28/3, 28/1 or 28/0. These results 
demonstrate that continuous CLA dietary supplementation for a longer 
period,       during  suckling  and  early  infancy,  increases  expression of the IgA  
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Figure 6. Effect of CLA on IgA gene expression in 28-day-old animals. Gene 
expression was evaluated in small intestine (A) and colon (B) by Real Time PCR. IgA 
gene expression was normalized using β-actin and are showed as percentage relative 
to values in age-matched reference animals (21/0 or 28/0). Values are expressed as 
mean ± SEM (n= 5). Significant differences: *P<0.05 vs. reference group (28/0); 
φP<0.05 vs. 28/1; ΨP<0.05 vs. 28/3. Modified of Pérez-Cano et al. [24].  
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Figure 7.  Effect of CLA on IgA in intestinal washes from 28-day-old rats. Secretory 
IgA was quantified in intestinal washes of small intestine by ELISA. Results are 
expressed as IgA protein (ng) referred to intestinal weight (g) used for the wash. 
Values are expressed as mean ± SEM (n= 9-10). Significant differences: *P<0.05 vs. 
28/0; φP<0.05 vs. 28/1; ΨP<0.05 vs. 28/3. Modified of Pérez-Cano et al. [24].  
 
gene and protein, thereby enhancing development of the rat’s mucosal 
defense system. This is the first in vivo report, to our knowledge, showing an 
increase of mucosal IgA after feeding CLA during early life [24]. In line with 
our data, Sugano et al. [15] reported an increase in IgA secretion from 
cultured mesenteric lymph nodes of 7-week-old rats, fed a 1% CLA 50:50 
isomer mix. 
 The specific mechanism by which CLA enhances IgA levels at mucosal 
sites remains unknown. But since CLA has been shown to suppress IL-4 
production in vitro [62], attenuate Th2 responses in challenged animals [63], 
and regulate the number and effectors functions of several lymphocytes [64], 
further studies should be addressed to elucidate whether it exist a direct 
enhancer mechanism of CLA on IgA-producing cells. 
 
1.7.2. Effect of CLA on TGF-β and PPARγ gene expression in small intestine  
and colon   
 
 Because IgA gene expression and intestinal production were increased 
after feeding CLA, we also studied molecules which could have a role in this 
process. In this sense, transforming growth factor (TGF)β gene expression 
was a candidate due to its involvement in the isotype switching process from 
IgM to IgA [65,66]. However, intestinal TGFβ gene expression was not 
modified in any of the CLA-supplemented groups during gestation, suckling 
and/or early infancy. Nonetheless, an influence of CLA on TGFβ cannot be 
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ruled out. If CLA is modulating the effects of TGFβ on IgA production, it is 
probably due to posttranscriptional and/or translational regulation, which are 
important in this cytokine, because it has been suggested that TGFβ mRNA 
levels do not completely correlate with the quantity of protein produced [67]. 
On the other hand, the increase of IgA as result of CLA supplementation 
might be independent of the isotype switching mechanism produced by 
TGFβ, which has been described, but is not completely defined [68].  
 On the other hand, two main mechanistic theories have been proposed to 
explain the immunoenhancing effects of dietary CLA: a PPARγ-dependent 
and a PPARγ-independent pathway [69]. The present study investigates 
PPARγ gene expression in the small intestine and colon of 21- and 28-day-
old animals fed standard and CLA-supplemented diets (Fig. 8). At both ages, 
there were no differences in PPARγ gene expression in small intestine between 
CLA and non-supplemented groups. However, PPARγ was up-regulated in 
colon tissue, particularly in 21-day-old animals fed CLA (21/5*, 21/5, and 21/3 
groups), when compared with reference animals (21/0) (Fig. 8A). This 2-fold 
up-regulation was only significant in the 21/5* group. Similar to the results 
found in 21-day-old animals, colon PPARγ gene expression was also up-
regulated in 28-day-old animals fed CLA (28/4, 28/3, and 28/1), when 
compared with reference animals (28/0) (Fig. 8B). Nevertheless, only the 28/3 
and 28/1 groups showed statistical differences, since 28/4 group had a great 
variability. Overall, CLA-supplemented rats showed higher PPARγ expression 
than non-supplemented animals.                       Specifically, the effects seem to be related to a  
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Figure 8.  Effect of CLA on colon PPARγ gene expression in 21- and 28-day-old 
animals. Gene expression was evaluated by Real Time PCR at the end of the suckling 
period (day 21; A) and 1 week after weaning (day 28; B). PPARγ gene levels were 
normalized using the β-actin gene and are expressed as percentage relative to values 
from age-matched reference animals (21/0 or 28/0). Values are expressed as mean      
± SEM (n= 5). Significant differences: *P<0.05 vs. age-matched reference group (21/0 
or 28/0). Modified of Pérez-Cano et al. [24].  
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dose-dependent manner that was proportional to the duration of 
supplementation over gestation, suckling, or early infancy. Thus, CLA 
modulated PPARγ expression in all the dietary conditions examined, even 
when animals were supplemented for only 1 week. 
 These results concur with findings from studies showing an increase of 
PPARγ mRNA expression associated with CLA supplementation in colon of 
healthy and ill mice and pigs [22,57,63,69]. Moreover, PPARγ up-regulation 
by CLA is in line with the results of Takamura et al. [70], who showed that 
specific natural or synthetic ligands of PPARγ can induce a mean 2- to 3-fold 
expression of this receptor in a positive feedback loop. In vitro studies have 
also indicated that the PPARγ activating capabilities of CLA are cell type-
dependent and isomer specific [69].  
 PPARγ comprises two isoforms, PPARγ1 and PPARγ2. Both are 
expressed in adipocytes, but PPARγ1 is expressed in T and B cells, 
monocytes, dendritic cells, and epithelial cells [71,72]. Hence, the effects of 
CLA found in the present study may be due to the interaction of CLA with 
PPARγ1. There are several possible options through which CLA might act. 
First, although a direct relationship between PPARγ increase and IgA gene 
expression has not been described, Ponferrada et al. [73] reported that PPARγ 
agonists can revert stress-induced decrease of IgA production in the colon 
mucosa, even beyond the IgA-controlled basal concentration. Moreover, it 
seems that this nuclear receptor acts through modulation of transcriptional 
factors such as NF-κB, AP1, and STAT1 [74,75], which are involved in      
B-cell regulatory processes. Second, recent research has also indicated close 
links between intestinal-microbial interactions and regulation of PPARγ 
expression by epithelial cells of colon tissue [76], suggesting that CLA may 
influence the natural mechanisms involved in intestinal homeostasis 
regulation. Lastly, it has been demonstrated that PPARγ regulates the 
epithelial differentiation process [77]. Thus, CLA may be modulating the 
entry of luminal antigen, the capacity for direct antigenic presentation, or 
even the transmission of antigen to dendritic cells from the intestinal mucosa. 
These hypotheses are supported by the fact that dendritic cell 
immunogenicity is regulated by PPARγ [78].  
 
1.7.3. Effect of CLA on rat mesenteric lymph nodes gene expression profiles      
 
 The data reported in above sections 1.7.1. and 1.7.2. provide scientific 
evidence of the impact of lipid nutrition, particularly the influence of the 
c9,t11-CLA isomer, on mucosal immunomodulation. On the other hand, it is 
known that food components play a role in influencing, either directly or 
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indirectly (through hormonal regulation), the expression of genes involved in 
immune responses [79]. Thus, further studies were developed to define the 
mechanism of action CLA at genic level in the intestinal compartment [80].  
 For that purpose, the gene expression profile in animals supplemented 
with CLA during gestation and suckling of mesenteric lymph nodes, sites of 
activation and proliferation of lymphocytes coming from the intestinal tissue 
(i.e. an inductor site), was determined. The specific GeneChip® Rat Genome 
230 2.0 (Affymettrix) and bioinformatic analyses (GeneSpring GX software) 
were used. It led to the identification of 123 genes differentially expressed in 
all CLA dietary approaches with respect to the reference group. Generation of 
a biological association network evidenced several genes, such as connective 
tissue growth factor (Ctgf), tissue inhibitor of metalloproteinase 1 (Timp1), 
galanin (Gal), synaptotagmin 1 (Syt1), growth factor receptor bound protein 
2 (Grb2), actin gamma 2 (Actg2) and smooth muscle alpha actin (Acta2), as 
highly interconnected nodes of the resulting network [80]. All these genes 
modulated by CLA supplementation may have a role on lymphoproliferation 
and mucosal immune responses in early life. 
 
2. Long-term feeding of CLA from gestation to adulthood: Effect 
on the immune system in adult rats       
 
 As previous studies have suggested that CLA intake during 
developmental phases may have effects later in life [22,23], this second part 
of the study was performed from gestation to adulthood. The aim was to 
ascertain whether the capacity to produce a specific immune response in 
ovalbumin (OVA)-sensitized adult rats is influenced by long-term feeding of 
an enriched diet containing an 80:20 CLA isomer mix of c9,t11- and t10,c12-
CLA, respectively [42].    
 
2.1. Experimental design                                             
 
 Pregnant Wistar rats at 7 days’ gestation were assigned to 1 of the 2 
dietary groups and after delivery, litters were kept with their dams until 
weaning (day 21). Thereafter, pups consumed the same diet as their mothers. 
The 2 dietary groups were the CLA group and the reference (REF) group 
(Fig. 9). The CLA group was constituted by rats whose dams were fed a 1% 
CLA diet (see section 1.2.) during gestation (2 wk) and suckling (3 wk); pups 
received CLA through the placenta and milk, respectively. From weaning 
until the end of the study (15-wk-old rats), animals were also fed 1% CLA 
diet. The total period of supplementation was 17 wk. Rats from the reference 
group were fed a standard diet throughout the 17 wk of study.          Nine-week-old  
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Week 15Day 7 of gestation Birth day (1) Day 21
Gestation (2 wk) Suckling (3 wk) Infancy (6 wk)
CLA supplemented animals Non-supplemented animals
CLA Diet                   
Dams’ Milk2
CLA Diet1                                                
Pups (17 wk)3:
Dams:
CLA diet                                        
Adult age (6 wk)
Week 9
Standard Diet                  
Dams’ MilkPups (0 wk):
Dams:
Standard diet                                    
Standard Diet
CLA group
REF group
ovalbumin
immunization4
 
 
Figure 9. Diagram of the experimental design beginning on day 7 of gestation until 
week 15 of life. 1 CLA arrives at the foetus by transplacental transfer. 2 CLA arrives at 
pups through the dams’ milk of dams. 3 Total period of CLA supplementation from 
gestation until 15 weeks of age. 4 Ovalbumin immunization by i.p. injection to           
9-week-old rats.    
 
rats from both groups were immunized with ovalbumin (OVA) emulsified with 
alum adjuvant by intraperitoneal (i.p.) injection. Six weeks after immunization, 
15-wk-old rats were sacrificed and immune status was assessed (Fig. 9). 
 
2.2. Effect of CLA on the polyclonal and antigen-specific cell immune 
response                                                                                                                                                                               
 
 Although the main goal was to examine whether a long-term CLA diet 
was able to modulate the capacity to generate an antigen (Ag)-specific cell 
immune response, the ex vivo capacity to generate a mitogen-induced 
immune response was also evaluated in isolated spleen lymphocytes by 
means of their ability to proliferate and to secrete IL-2 [42]. The Figure 10A 
shows that spleen cells from rats fed CLA throughout the study (17 wk) had a 
∼10% lower proliferative response than reference rats after mitogen-
stimulation. This down-regulatory effect by dietary CLA was not due to cell 
viability loss, because viability from the CLA after mitogen addition was 
comparable to that of reference cells. Secretion of IL-2 was also lower in cell 
cultures of CLA-fed rats than in those of rats fed the standard diet (Fig. 10B). 
These results agree with those found in the 28-day-old assessment (see 
section 1.6.3.) and those of Tricon et al. [44], who showed that peripheral 
blood mononuclear cells from subjects fed either c9,t11- or t10,c12-CLA 
isomers, after mitogen-stimulation, decreased CD69 expression, which 
strongly correlates with lymphocyte proliferation. However, there are other 
studies using diverse CLA isomer mixtures that described either increased 
splenocyte proliferation or no effect after stimulus addition [45,47,81].  
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 Regarding the long-term effects of dietary CLA supplementation on Ag-
specific immune response, the lymphoproliferative capacity after OVA 
addition was evaluated. Reference and CLA groups had a higher (2- to 3--
fold) splenocyte proliferation after OVA stimulation than unstimulated cells 
and after control protein addition (Fig. 11). In terms of specific proliferative 
response,  splenocytes  recovered  from  OVA-immunized  rats  fed    CLA       had  
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Figure 10.  Proliferative response (A), and IL-2 production (B) of unstimulated (US) 
and mitogen-stimulated (S) spleen cells from rats fed a CLA or standard diet (CLA or 
REF groups). Polyclonal proliferative response was determined after stimulating with 
PMA/Io for 72 h. IL-2 was quantified by ELISA in 24-h supernatant cultures. Data are 
means ± SEM (n= 20). Significant differences: *P<0.05 vs. US cells within the same 
dietary group; φP<0.05 vs. reference group. Modified of Ramírez-Santana et al. [42].  
 
0.0
0.5
1.0
1.5
2.0
2.5
*
* δ 
δ φ 
Pr
ol
ife
ra
tio
n
(O
D
 u
ni
ts
)
REF (US) 
REF (CAS)
REF (OVA)
CLA (US)
CLA (CAS)
CLA (OVA)
Pr
ol
ife
ra
tio
n
(O
D
 u
ni
ts
)
 
 
Figure 11.  OVA-specific proliferative response of spleen cells from rats fed the CLA 
or the standard diet (CLA or REF groups). Specific response was determined after 
OVA stimulation for 96 h. Control protein (casein, CAS) and only medium 
(unstimulated cells, US) were used as negative reference controls. Data are means ± 
SEM (n= 20). Significant differences: *P<0.05 vs. US cells within a diet group; 
δP<0.05 vs. CAS-stimulated cells within a diet group. φP<0.05 vs. reference group. 
Modified of Ramírez-Santana et al. [42].  
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higher (∼275%) lymphoproliferative response to OVA than splenocytes 
recovered from OVA-immunized rats fed the standard diet (∼165%). The 
OVA-specific splenocyte proliferation enhancement by CLA found here 
agrees with that reporting a higher specific proliferative response of T CD8+ 
lymphocytes from pigs fed a CLA diet (∼50:50 isomers mix) [50,51]. In 
addition, following hepatitis B vaccination, specific lymphocyte proliferation 
was higher in humans fed CLA 50:50 than in the control group [45]. 
Conversely, Kelley et al. [82] showed no effect on influenza-specific 
proliferation in humans after feeding CLA, but in this case, the two main 
isomers used contributed only 40% of total CLA isomers, whereas in most of 
the studies affecting proliferative response, the main isomers made up ∼80% 
of all CLA isomers. 
 
2.3. Effect of CLA on the Ag-specific systemic and mucosal humoral 
immune responses  
 
 To ascertain long-term CLA diet effects on systemic humoral immune 
response, we have quantified serum OVA-specific antibody concentration, 
ex vivo spleen anti-OVA antibody production, and spleen anti-OVA-
antibody-secreting cells (SC) number. Long-term dietary CLA did not 
modify the humoral immune response against the OVA-specific challenge 
either in serum or in splenocyte supernatants. However, using enzyme-
linked immunosorbent spot technique (ELISPOT) we counted spontaneous 
anti-OVA IgG-, IgM-, and IgA-SC in spleens and we found that OVA-
immunized rats had more spleen anti-OVA IgA-SC in CLA-fed rats (15.6 ± 
3.5; mean ± SEM) than in reference group (11.9 ± 1.9). These results show 
overall that, although OVA-primed spleen B cells produced specific anti-
OVA antibodies after later OVA contact, rats fed a CLA diet did not 
generate a higher systemic (serum and spleen) humoral response against 
OVA. This might suggest that the presence of 1% CLA in the diet increased 
neither the number of primed memory B cells nor their ability to produce 
specific antibodies. Our results agree with others carried out in humans and 
animals fed CLA [51,82,83], although Albers et al. [45] showed a higher 
concentration of anti-B hepatitis antibodies in subjects consuming CLA 
50:50 capsules. On the other hand, CLA feeding did not modify total serum 
Ig concentrations. This result agrees with many others [16,81,82] but 
disagrees with a human study that reported increased IgM and IgA plasma 
concentrations after consuming CLA [36]. Nevertheless, better humoral 
enhancing effects were observed in developing states (see section 1.6.), 
although specific adaptive responses were not addressed in such studies 
[20,21].  
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 Regarding mucosal sites, we found interesting CLA results in this 
particular immune compartment: the dietary CLA modulated mucosal IgA 
production. Long-term dietary CLA increased the anti-OVA IgA synthesis in 
the intestinal mucosa ∼75% (Fig. 12), although CLA did not modify total gut 
IgA. These data suggest that the CLA diet had a restricted enhancement 
effect on OVA-specific IgA intestinal production but not a general effect on 
humoral immunity.  
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Figure 12.  OVA-specific IgA in intestinal washes from rats fed the CLA or the 
standard diet (CLA or REF groups). Six weeks after immunization, secretory IgA was 
quantified in intestinal washes of small intestine by ELISA. Results are expressed 
relative to the reference group, which was set at 100%. Data are means ± SEM (n= 
20). Significant differences: *P<0.05 vs. reference group. Modified of Ramírez-
Santana et al. [42].  
 
 The boost of specific intestinal IgA is of great importance, because this 
Ig is the main isotype present in all mucosa and confers high protection 
against foreign substances and microbe entry through the intestine, as well as 
by other mucosal compartments, due to specific secretory IgA homing among 
mucosal sites [84]. Thus, to our knowledge, this is the first time that a CLA 
supplementation enhancement of Ag-specific mucosal responses has been 
reported.  
 Because the CLA diet increased only intestinal-specific IgA, but not 
spleen or serum antibodies, it is plausible to suggest that CLA may be 
enhancing B cells present in the lamina propria or even promoting the IgA-
secreting cell migration to the intestine from other immune compartments. 
This particular type of immunoenhancement induced by CLA, acting on a 
specific cell subset, is likely, because Bassaganya-Riera et al. [64] reported a 
higher percentage of a particular immune cell subset, but not of others, in 
swine fed CLA.  
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3. Conclusions 
 
 The data reported in this chapter contribute to the scientific evidence pointing 
to the potential impact of lipid nutrition on immune system development during 
early life, particularly the effect of the c9,t11-CLA isomer, the main CLA isomer 
present in breast milk. Although further studies should be carried out to elucidate 
CLA signalling mechanisms, the results presented herein by the dietary 
supplementation with an 80:20 c9,t11:t10,c12 CLA mix demonstrate that: 
 
 - CLA is transferred from the dams’ diet to breast milk and later is 
  efficiently incorporated by their pups. This supplementation also 
  increases dam’s milk IgG and IgA concentrations. 
 - The capacity of immune cells to synthesise antibodies, i.e. humoral 
  immune response, is enhanced by CLA during gestation, suckling 
  and/or early infancy. It is demonstrated, in vivo and ex vivo, by the 
  increase of serum IgG concentration and spleen IgM production, 
  respectively, in CLA fed animals.  
 - CLA supplementation during suckling and early infancy down-
  regulates the systemic lymphoproliferative response and increases 
  the secretion of some Th2 cytokines during early age.   
 - CLA increases the intestinal immune defenses of rats during the first 
  stages of life. CLA-dependent enhancement of humoral mucosal 
  immune response was demonstrated by the striking increase of 
  intestinal IgA expression in early infant rats fed CLA along life. 
  Moreover, PPARγ gene expression levels were up-regulated in a 
  supplementation period-dependent manner. 
 - It is clearly shown that the effects of CLA are more pronounced the 
  earlier  and  more long-lasting CLA  dietary  supplementation. 
  Specifically, the importance of the continuous supplementation 
  during gestation-suckling or suckling-early infancy is evidenced by 
  the observation of some immunomodulatory effects only produced 
  when CLA is received during these periods.  
 - CLA diet  administered from  gestation to  adulthood enhances 
  specific systemic cell-mediated immunity as well as the mucosal 
  IgA immune response, whereas it down-regulates the polyclonal 
  activation of the immune system. These data support the long-term 
  effects of dietary CLA on the immune system. 
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